to plan ahead for this year. Lilly's Zepbound and Novo's Wegovy dominate a market for weight-loss treatments that analysts estimate could be a $150 billion market by the early 2030s. Both the ...

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

MORGANTOWN – WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for ...

Ozempic and other glucagon-like peptide-1 (GLP-1) agonists are a transformative new class of medicines for the treatment of ...

The increase in weight loss with the higher dose was impressive, but still lower than has been achieved in clinical trials of Eli Lilly's rival obesity therapy Zepbound (tirzepatide), which helped ...

Viking Therapeutics got the market's attention with robust phase 2 results for VK2735, a potential weight loss therapy. VK2735 is a dual GLP-1/GIP medicine, the same class as Eli Lilly's Zepbound.

The remarkable efficacy of new diabetes and weight loss medicines like Ozempic and Mounjaro have been one of the biggest health stories of recent years. Despite rising rates of diabetes and obesity, ...

“We will revisit our build out plan ... Zepbound are part of a wave of diabetes and obesity medications known as GLP-1 receptor agonists that are soaring in popularity globally due to the amount ...